Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED
██.█% Sign up free to reveal

Inhibikase Therapeutics, Inc. (IKT) AI Forecast

Our AI detected a significant signal for Inhibikase Therapeutics, Inc.. Create a free account and follow it to see the exact price target.

✓ Free account • ✓ 30-day free trial

$IKT Bullish Signal Full forecast available
Sign Up Free

Inhibikase Therapeutics, Inc. (IKT) Stock Forecast Aug. 19, 2026

Inhibikase Therapeutics, Inc. (IKT) AI Stock Price Forecast & Investment Analysis

Inhibikase Therapeutics, Inc. Stock Price Chart and Technical Analysis

Loading chart...

Inhibikase Therapeutics, Inc. (IKT) - Comprehensive Stock Analysis & Investment Research

Deep dive into Inhibikase Therapeutics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on August 19, 2026, 2:01 a.m. (UTC)

Inhibikase Therapeutics, Inc. Investment Summary

When evaluating whether Inhibikase Therapeutics, Inc. (IKT) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Inhibikase Therapeutics, Inc. (IKT) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $318 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.

Financial Performance Analysis

Our comprehensive financial analysis covers Inhibikase Therapeutics, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Inhibikase Therapeutics, Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Inhibikase Therapeutics, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Inhibikase Therapeutics, Inc.

Sign Up Free
Corporate Identity

Inhibikase Therapeutics, Inc. (Stock Symbol: IKT) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Inhibikase Therapeutics, Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Inhibikase Therapeutics, Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Inhibikase Therapeutics, Inc....

Unlock Full Company Profile

Get complete details about Inhibikase Therapeutics, Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Inhibikase Therapeutics, Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Inhibikase Therapeutics, Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Inhibikase Therapeutics, Inc....

Unlock Financial Analysis

Get complete financial metrics for Inhibikase Therapeutics, Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Inhibikase Therapeutics, Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Inhibikase Therapeutics, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.

Industry Competitive Landscape

Inhibikase Therapeutics, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-43 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Inhibikase Therapeutics, Inc. (IKT) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Inhibikase Therapeutics, Inc. stock analysis.

Deep dive into Inhibikase Therapeutics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Inhibikase Therapeutics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Inhibikase Therapeutics, Inc.:

P/B Ratio 2.08x
Market Cap $318M
Book Value/Share $1.16
FCF/Share $-0.32
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Inhibikase Therapeutics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Inhibikase Therapeutics, Inc.: An ROE of -6.9% indicates room for improvement in shareholder value creation.

ROE -6.9%
ROA -6.5%
Operating Margin -186.6%
Net Margin -187.4%
EBT Margin -186.6%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Inhibikase Therapeutics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Inhibikase Therapeutics, Inc.:

D/E Ratio 0.07x
Financial Leverage 1.07x
Interest Coverage -12.2x
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Inhibikase Therapeutics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Inhibikase Therapeutics, Inc.: Free cash flow of $-43M indicates cash challenges that need attention.

Operating Cash Flow -$16M
Free Cash Flow -$43M
Capital Spending -$27M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Inhibikase Therapeutics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Inhibikase Therapeutics, Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Inhibikase Therapeutics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Inhibikase Therapeutics, Inc.:

Income Statement
Operating Income -$10M
Net Income -$10M
R&D Expense $10M
SG&A Expense $6M
Balance Sheet Highlights (% Of Assets)
Total Liabilities 10%
Dividend & Shareholder Information
Shares Outstanding 132M
Growth Metrics (YoY)
Net Income Growth -187.4%

Latest Inhibikase Therapeutics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Inhibikase Therapeutics, Inc. (IKT) stock price and investment outlook.

📰 Loading...

Where IKT sits on the market map

Explore the map →

Inhibikase Therapeutics, Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Inhibikase Therapeutics, Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $198M x 3.5x
ABPO ██% $1M x x
ACOG ██% $187M x 3.5x
ADAPY ██% $8M x x
ADMA ██% $2.15B 12.7x 5.3x
ADPT ██% $3.91B x 27.3x
AGEN ██% $305M 3.3x x
AGTX ██% $800K x x
AIM ██% $6M x 0.8x
ALEC ██% $247M x x
ALGS ██% $42M x 1.3x
ALLO ██% $718M x 1.7x
ALVO ██% $1.23B x x
AMGN ██% $226.72B 25.9x 19.4x
APGE ██% $10.14B x x
APTN ██% $57M x x
APTOF ██% $4M x x
ARGX ██% $61.45B x x
ARMP ██% $166M x x
ARTV ██% $571M x 1.6x
ATRA ██% $79M x x
ATYR ██% $51M x 1.0x
AURA ██% $844M x 2.7x
AUTL ██% $607M x 8.1x
AVXL ██% $297M x 2.3x
BCAB ██% $5M x x
BCDA ██% $15M x 5.4x
BCLI ██% $16M x x
BCRX ██% $2.45B x x
BDTX ██% $118M x 1.2x
BEAM ██% $2.74B x 2.6x
BIIB ██% $31.29B 22.8x 1.7x
BKHA ██% $49M 96.2x x
BNTX ██% $23.30B x x
CABA ██% $493M x 2.3x
CADL ██% $917M x 7.3x
CCCC ██% $514M x 2.1x
CELZ ██% $7M x 0.8x
CERO ██% $480K x x
CGEM ██% $1.34B x 4.2x
CGEN ██% $225M 3.2x 2.2x
CGON ██% $6.74B x 6.6x
CGTX ██% $94M x 2.9x
CHRS ██% $178M x 2.9x
CLDI ██% $3M x 1.0x
CLLS ██% $306M x x
CMPX ██% $416M x 2.5x
CPMV ██% $440K x x
CRDF ██% $71M x 2.7x
CRDL ██% $221M x x
CRIS ██% $4M x 0.9x
CRSP ██% $5.25B x 3.0x
CSBR ██% $71M x 18.0x
CVM ██% $27M x 2.5x
DBVT ██% $908M x 5.7x
DNA ██% $416M x 1.0x
DNLI ██% $3.88B x 4.7x
DTIL ██% $209M x 4.6x
DYAI ██% $28M x x
EDIT ██% $436M x 4.1x
EIKN ██% $567M x 1.2x
ELUT ██% $43M 0.8x 2.7x
ENGN ██% $114M x 0.5x
ENTX ██% $143M x 19.7x
ENZN ██% $67M x 0.4x
ESLA ██% $33M x x
EVAX ██% $26M x x
EXEL ██% $13.02B 15.1x 7.1x
EXOZ ██% $58M x 15.9x
FATE ██% $306M x 2.0x
FDMT ██% $803M x 2.0x
FENC ██% $414M x 9.8x
GILD ██% $171.70B x 14.5x
GLUE ██% $1.32B x 2.7x
GNTA ██% $63M x 5.0x
GPLB ██% $180K x x
GRML ██% $31M x 0.5x
HALO ██% $11.25B 27.2x 78.4x
HUMA ██% $168M x 5.4x
IBRX ██% $7.97B x x
IKT ██% $318M x 2.1x
IMA ██% $66M x 0.5x
IMCR ██% $1.76B x 4.2x
IMTX ██% $1.27B x x
IMVT ██% $8.63B x 11.7x
INAB ██% $11M x 0.6x
INKT ██% $60M x x
INMB ██% $60M x 3.0x
INTS ██% $13M x 1.4x
IOVA ██% $3.16B x 4.3x
IPSC ██% $349M x 1.5x
IVVD ██% $213M x 1.2x
JATT ██% $100M x 0.5x
JSPR ██% $26M x 18.6x
KLRS ██% $97M x 1.7x
KOD ██% $2.60B x 42.5x
KRYS ██% $9.83B 40.7x 7.2x
KYMR ██% $9.72B x 6.4x
KYTX ██% $503M x 3.0x
LCTX ██% $271M x 4.4x
LENZ ██% $152M x 0.7x
LIFE ██% $3.38B x 69.3x
LIMN ██% $9M x 28.8x
LONA ██% $75M x 2.2x
LXEO ██% $381M x 1.6x
MAZE ██% $1.61B x 3.6x
MESO ██% $2.02B x x
MGTX ██% $1.27B 16.1x 5.9x
MGX ██% $46M x 0.4x
MOLN ██% $173M x x
MRNA ██% $25.26B x 3.7x
NBIX ██% $15.52B 22.0x 4.2x
NMRA ██% $296M x 6.7x
NVAX ██% $1.33B x x
OCGN ██% $458M x x
OTLK ██% $183M x x
PALI ██% $371M x 3.1x
PASG ██% $15M x 3.3x
PCVX ██% $8.41B x 3.1x
PHGE ██% $2M x x
PLUR ██% $17M x x
PLX ██% $178M 9.4x 2.5x
PMCB ██% $6M x 0.2x
PRME ██% $558M x 14.0x
PROK ██% $531M x x
PTHS ██% $102M x x
QGEN ██% $9.32B x 2.5x
QNCX ██% $35M x x
REPL ██% $1.26B x 11.9x
RGEN ██% $9.41B 226.6x 4.5x
RGNX ██% $711M x 9.9x
RLAY ██% $4.34B x 4.9x
RVMD ██% $43.64B x 16.8x
RXRX ██% $1.69B x 1.8x
SABS ██% $309M x 1.4x
SANA ██% $1.06B x 6.9x
SCLX ██% $48M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $70M x x
SLDB ██% $941M x 2.5x
SLXN ██% $570K x 12.9x
SNTI ██% $14M x x
SRRK ██% $6.39B x 25.2x
SRZN ██% $282M x x
STRO ██% $373M x x
TARA ██% $232M x 1.4x
TARS ██% $3.07B x 8.9x
TCRX ██% $52M x 0.8x
TECH ██% $11.34B 103.5x 5.4x
TECX ██% $689M x 3.1x
TIL ██% $50M x 0.5x
TNYA ██% $154M x 2.2x
TSHA ██% $2.03B x 5.2x
TVGN ██% $29M x x
TWST ██% $7.45B x 16.7x
VACH ██% $541M 80.4x x
VALN ██% $651M x x
VCEL ██% $2.27B 93.6x 6.1x
VIR ██% $1.59B x 1.6x
VIVS ██% $4M x x
VOR ██% $1.25B 2.0x x
VXRT ██% $121M 3.2x 1.5x
VYGR ██% $199M x 1.3x
WINT ██% $40K x x
XFOR ██% $406M x 2.6x
ZEOX ██% $11M x 15.3x
ZIVO ██% $16M x x
ZURA ██% $555M x 2.8x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Inhibikase Therapeutics, Inc. Stock Forecast

How accurate are Inhibikase Therapeutics, Inc. stock predictions?

Our AI model shows a 31% Spearman correlation coefficient for IKT predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Inhibikase Therapeutics, Inc. stock price forecasts?

Our analysis considers Inhibikase Therapeutics, Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Inhibikase Therapeutics, Inc. a good investment in 2026?

Based on our AI analysis, Inhibikase Therapeutics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Inhibikase Therapeutics, Inc. forecasts updated?

Inhibikase Therapeutics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Inhibikase Therapeutics, Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...